About this Journal Submit a Manuscript Table of Contents
Sarcoma
Volume 2013 (2013), Article ID 608964, 11 pages
http://dx.doi.org/10.1155/2013/608964
Research Article

Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells

1Centre for Cancer Research, Monash Institute of Medical Research, Monash University, 27-31 Wright St, Clayton, VIC 3168, Australia
2Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, VIC 3002, Australia
3Andrew Love Cancer Centre, Deakin University, Barwon Health, 70 Swanston St, Geelong, VIC 3220, Australia

Received 31 December 2012; Accepted 25 January 2013

Academic Editor: C. Fisher

Copyright © 2013 Jason E. Cain et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. H. Luu, E. R. Wagner, G. Luther et al., “Defective osteogenic differentiation in the development of osteosarcoma,” Sarcoma, vol. 2011, Article ID 325238, 12 pages, 2011. View at Publisher · View at Google Scholar
  2. H. D. Dorfman and B. Czerniak, “Bone cancers,” Cancer, vol. 75, no. 1, supplement, pp. 203–210, 1995. View at Scopus
  3. S. B. Lansky, J. L. Black, and N. U. Cairns, “Childhood cancer. Medical costs,” Cancer, vol. 52, no. 4, pp. 762–766, 1983. View at Scopus
  4. M. P. Link, A. M. Goorin, and A. W. Miser, “The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity,” The New England Journal of Medicine, vol. 314, no. 25, pp. 1600–1606, 1986. View at Scopus
  5. A. Longhi, C. Errani, M. De Paolis, M. Mercuri, and G. Bacci, “Primary bone osteosarcoma in the pediatric age: state of the art,” Cancer Treatment Reviews, vol. 32, no. 6, pp. 423–436, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Kansara and D. M. Thomas, “Molecular pathogenesis of osteosarcoma,” DNA and Cell Biology, vol. 26, no. 1, pp. 1–18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. P. A. Meyers, G. Heller, and J. Healey, “Retrospective review of neoadjuvant chemotheraphy for osteogenic sarcoma,” Journal of the National Cancer Institute, vol. 84, no. 3, pp. 202–204, 1992. View at Publisher · View at Google Scholar · View at Scopus
  8. A. A. Sandberg and J. A. Bridge, “Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors,” Cancer Genetics and Cytogenetics, vol. 145, no. 1, pp. 1–30, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. S. L. Berger, T. Kouzarides, R. Shiekhattar, and A. Shilatifard, “An operational definition of epigenetics,” Genes and Development, vol. 23, no. 7, pp. 781–783, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. X. Ma, H. H. Ezzeldin, and R. B. Diasio, “Histone deacetylase inhibitors: current status and overview of recent clinical trials,” Drugs, vol. 69, no. 14, pp. 1911–1934, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Leder and P. Leder, “Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells,” Cell, vol. 5, no. 3, pp. 319–322, 1975. View at Scopus
  12. A. Leder, S. Orkin, and P. Leder, “Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis,” Science, vol. 190, no. 4217, pp. 893–894, 1975. View at Scopus
  13. J. M. Wagner, B. Hackanson, M. Lübbert, and M. Jung, “Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy,” Clinical Epigenetics, vol. 1, no. 3-4, pp. 117–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. S. M. Taylor and P. A. Jones, “Multiple new phenotypes induced in 10T 1/2 and 3T3 cells treated with 5-azacytidine,” Cell, vol. 17, no. 4, pp. 771–779, 1979. View at Scopus
  15. M. Kansara, M. Tsang, L. Kodjabachian et al., “Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice,” Journal of Clinical Investigation, vol. 119, no. 4, pp. 837–851, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Benjamini and Y. H. Y, “Controlling the false discovery rate—a practical and powerful approach to multiple testing,” Journal of the Royal Statistical Society B, vol. 57, no. 1, pp. 289–300, 1995.
  17. P. N. Munster, T. Troso-Sandoval, N. Rosen, R. Rifkind, P. A. Marks, and V. M. Richon, “The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells,” Cancer Research, vol. 61, no. 23, pp. 8492–8497, 2001. View at Scopus
  18. V. M. Richon, T. W. Sandhoff, R. A. Rifkind, and P. A. Marks, “Histone deacetylase inhibitor selectively induces p21WAF1 expressjon and gene-associated histone acetylation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 18, pp. 10014–10019, 2000. View at Scopus
  19. G. Floris, M. Debiec-Rychter, R. Sciot et al., “High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model,” Clinical Cancer Research, vol. 15, no. 12, pp. 4066–4076, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Thomas and M. Kansara, “Epigenetic modifications in osteogenic differentiation and transformation,” Journal of Cellular Biochemistry, vol. 98, no. 4, pp. 757–769, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. C. R. Walkley, R. Qudsi, V. G. Sankaran et al., “Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease,” Genes and Development, vol. 22, no. 12, pp. 1662–1676, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Shen, H. Hovhannisyan, J. B. Lian et al., “Transcriptional induction of the osteocalcin gene during osteoblast differentiation involves acetylation of histones H3 and H4,” Molecular Endocrinology, vol. 17, no. 4, pp. 743–756, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. R. B. Vega, K. Matsuda, J. Oh et al., “Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis,” Cell, vol. 119, no. 4, pp. 555–566, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. E. J. Arnsdorf, P. Tummala, A. B. Castillo, F. Zhang, and C. R. Jacobs, “The epigenetic mechanism of mechanically induced osteogenic differentiation,” Journal of Biomechanics, vol. 43, no. 15, pp. 2881–2886, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. D. D. Cheng, Q. C. Yang, Z. C. Zhang, C. X. Yang, and Y. W. Liu, “Antitumor activity of histone deacetylase inhibitor A in osteosarcoma cells,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 4, pp. 1395–1399, 2012.
  26. T. Imai, S. Adachi, K. Nishijo et al., “FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells,” Oncogene, vol. 22, no. 58, pp. 9231–9242, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Thayanithy, C. Park, A. L. Sarver et al., “Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines,” PLoS One, vol. 7, no. 9, Article ID 43720, 2012. View at Publisher · View at Google Scholar
  28. L. A. Wittenburg, L. Bisson, B. J. Rose, C. Korch, and D. H. Thamm, “The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin,” Cancer Chemotherapy and Pharmacology, vol. 67, no. 1, pp. 83–92, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Lee, J. R. Park, M. S. Seo et al., “Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells,” Cell Proliferation, vol. 42, no. 6, pp. 711–720, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. D. M. Vigushin, S. Ali, P. E. Pace et al., “Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo,” Clinical Cancer Research, vol. 7, no. 4, pp. 971–976, 2001. View at Scopus